Compare

Compare archived captures

This view highlights text differences between two archived captures. It does not interpret meaning or provide guidance.

Descriptive changes only

This comparison highlights text changes between archived captures. It does not interpret the change or provide medical advice. For up-to-date recommendations, always consult the official source website.

Need to cite this comparison? See /cite.

Earlier capture

Register of Innovative Drugs - Canada.ca

Apr 18, 2025

legacy-hc-2025-04-21

ID 211673

Later capture

Register of Innovative Drugs - Canada.ca

Jan 1, 2026

hc-20260101

ID 404925

updated6 sections changed
6 sections changed0 added0 removed+106 / -120 linesChange ratio: 8%
---
+++
@@ -1,8 +1,9 @@
Register of Innovative Drugs
Guidance Document: Data Protection under C.08.004.1 of the Food and Drug Regulations
[2010-03-08]
-Register Of Innovative Drugs [Updated: 2025-04-15]
-(PDF, 290 KB)
+Do not change this link. Replace what is in the dam
+Register Of Innovative Drugs [Updated: 2025-12-23]
+(PDF, 296 Kb)
Contact:
Office of Patented Medicines and Liaison
Products for Human Use - Active Data Protection Period
@@ -18,8 +19,7 @@
Innovative Drug
Manufacturer
Drug(s) Containing the Medicinal Ingredient / Variations
-Notice of Compliance Date
-yyyy-mm-dd
+Notice of Compliance Date yyyy-mm-dd
6 Year
"No File"
Date
@@ -77,8 +77,8 @@
N/A
2020-07-31
2026-07-31
-N/A
-2028-07-31
+Yes
+2029-01-31
amivantamab
254440
Rybrevant
@@ -97,15 +97,6 @@
2029-06-16
N/A
2031-06-16
-mRNA encoding SARS-CoV-2 spike protein, 5'(m7G-5'-ppp-5'-Gm) cap, 100-nucleotide 3' poly(A) tail
-275936
-Spikevax
-Moderna Biopharma Canada Corporation
-N/A
-2023-09-12
-2029-09-12
-Yes
-2032-03-12
anifrolumab
246187
Saphnelo
@@ -133,15 +124,6 @@
2023-11-06
Yes
2026-05-06
-antihemophilic factor (recombinant), pegylated
-189709
-Adynovate
-Takeda Canada Inc.
-N/A
-2016-11-17
-2022-11-17
-Yes
-2025-05-17
antihemophilic factor (recombinant, B-domain deleted, pegylated) (also known as damoctocog alfa pegol)
210935
Jivi
@@ -158,17 +140,8 @@
N/A
2025-03-26
2031-03-26
-N/A
-2033-03-26
-antihemophilic factor VIII (recombinant), singlechain (also known as lonoctocog alfa)
-190891
-Afstyla
-CSL Behring Canada Inc.
-N/A
-2016-12-12
-2022-12-12
-Yes
-2025-06-12
+Yes
+2033-09-26
antihemophilic factor VIII (recombinant, B-domain truncated), PEGylated (turoctocog alfa pegol)
218531
Esperoct
@@ -187,6 +160,15 @@
2024-07-03
N/A
2026-07-03
+artesunate
+285622
+Amivas - Artesunate
+Amivas Ireland Ltd.
+N/A
+2025-07-04
+2031-07-04
+Yes
+2034-01-04
asciminib hydrochloride
255700
Scemblix
@@ -196,15 +178,6 @@
2028-06-23
N/A
2030-06-23
-atezolizumab
-196843
-Tecentriq
-Hoffmann-La Roche Limited
-N/A
-2017-04-12
-2023-04-12
-Yes
-2025-10-12
atogepant
253186
Qulipta
@@ -286,6 +259,15 @@
2024-08-17
N/A
2026-08-17
+belantamab mafodotin
+288908
+Blenrep
+GlaxoSmithKline Inc.
+N/A
+2025-07-18
+2031-07-18
+N/A
+2033-07-18
belumosudil mesylate
245791
Rezurock
@@ -304,6 +286,15 @@
2028-07-11
N/A
2030-07-11
+bempedoic acid
+291745
+Nilemdo
+HLS Therapeutics Inc.
+N/A
+2025-11-14
+2031-11-14
+N/A
+2033-11-14
benralizumab
204008
Fasenra
@@ -349,24 +340,6 @@
2027-03-02
N/A
2029-03-02
-botulism antitoxin heptavalent C/ D/F/ G – (equine)
-190645
-Bat
-Emergent BioSolutions Inc.
-N/A
-2016-12-08
-2022-12-08
-Yes
-2025-06-08
-brexpiprazole
-192684
-Rexulti
-Otsuka Pharmaceutical Co. Ltd.
-N/A
-2017-02-16
-2023-02-16
-Yes
-2025-08-16
brexucabtagene autoleucel
246355
Tecartus
@@ -403,6 +376,15 @@
2026-03-12
N/A
2028-03-12
+bulevirtide acetate
+293441
+Hepcludex
+Gilead Sciences Canada, Inc.
+N/A
+2025-08-08
+2031-08-08
+N/A
+2033-08-08
burosumab
216239
Crysvita
@@ -563,8 +545,8 @@
N/A
2024-06-20
2030-06-20
-N/A
-2032-06-20
+Yes
+2032-12-20
ciltacabtagene autoleucel
262122
Carvykti
@@ -574,6 +556,15 @@
2029-02-09
N/A
2031-02-09
+cipaglucosidase alfa
+284815
+Pombiliti
+Amicus Therapeutics Canada Inc.
+N/A
+2025-04-14
+2031-04-14
+N/A
+2033-04-14
clascoterone
265619
Winlevi
@@ -610,24 +601,15 @@
2024-06-07
Yes
2026-12-07
-cysteamine bitartrate
-191347
-Procysbi
-Horizon Pharma Ireland Ltd.
-N/A
-2017-06-13
-2023-06-13
-Yes
-2025-12-13
-fezolinetant
-280470
-Veozah
-Astellas Pharma Canada, Inc.
-N/A
-2024-12-02
-2030-12-02
-N/A
-2032-12-02
+crovalimab
+285444
+Piasky
+Hoffmann-La Roche Limited
+N/A
+2025-06-04
+2031-06-04
+Yes
+2033-12-04
dacomitinib
214572
Vizimpro
@@ -700,6 +682,15 @@
2031-01-17
N/A
2033-01-17
+delgocitinib
+282015
+Anzupgo
+Leo Pharma Inc.
+N/A
+2025-08-25
+2031-08-25
+N/A
+2033-08-25
deucravacitinib
259397
Sotyktu
@@ -754,15 +745,6 @@
2023-11-30
Yes
2026-05-30
-durvalumab
-202953
-Imfinzi
-AstraZeneca Canada Inc.
-N/A
-2017-11-03
-2023-11-03
-N/A
-2025-11-03
ebola zaire vaccine (rVSVΔG-ZEBOV-GP, live)
256568
Ervebo
@@ -781,15 +763,6 @@
2024-10-03
N/A
2026-10-03
-edoxaban
-187363
-Lixiana
-Servier Canada Inc.
-N/A
-2016-11-04
-2022-11-04
-Yes
-2025-05-04
efgartigimod alfa
267438
Vyvgart
@@ -799,6 +772,15 @@
2029-09-19
N/A
2031-09-19
+elafibranor
+287772
+Iqirvo
+Ipsen Biopharmaceuticals Canada Inc.
+N/A
+2025-04-25
+2031-04-25
+N/A
+2033-04-25
elagolix
209513
Orilissa
@@ -827,15 +809,15 @@
2027-06-18
Yes
2029-12-18
-eliglustat tartrate
-183050
-Cerdelga
-Sanofi-Aventis Canada Inc.
-N/A
-2017-04-21
-2023-04-21
-N/A
-2025-04-21
+elinzanetant
+289506
+Lynkuet
+Bayer Inc.
+N/A
+2025-07-23
+2031-07-23
+N/A
+2033-07-23
elranatamab
273519
Elrexfio
@@ -875,7 +857,7 @@
enfortumab vedotin
251438
Padcev
-Seagen Inc.
+Pfizer Canada ULC
N/A
2021-10-29
2027-10-29
@@ -1062,6 +1044,15 @@
2027-04-22
Yes
2029-10-22
+fezolinetant
+280470
+Veozah
+Astellas Pharma Canada, Inc.
+N/A
+2024-12-02
+2030-12-02
+N/A
+2032-12-02
fidanacogene elaparvovec
275853
Beqvez
@@ -1083,7 +1074,7 @@
flibanserin
189352
Addyi
-Searchlight Pharma Inc.
+Sprout Pharmaceuticals, Inc.
N/A
2018-02-27
2024-02-27
@@ -1134,15 +1125,6 @@
2030-09-10
N/A
2032-09-10
-gadoterate meglumine
-186333
-Dotarem
-Guerbet
-N/A
-2016-11-26
-2022-11-26
-Yes
-2025-05-26
galcanezumab
219521
Emgality
@@ -1152,6 +1134,15 @@
2025-07-30
N/A
2027-07-30
+garadacimab
+280174
+Andembry
+CSL Behring Canada Inc.

Diff output was truncated for readability.